Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who cur... Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Show more
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer PR Newswire AUSTIN, Texas, Nov. 20, 2024 License includes...
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting PR Newswire AUSTIN, Texas, Nov. 5, 2024 REQORSA...
Genprex to Participate in 2024 BIO Europe Conference PR Newswire AUSTIN, Texas, Oct. 31, 2024 AUSTIN, Texas, Oct. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:...
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma PR Newswire AUSTIN, Texas, Oct. 28...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.53 | -31.1764705882 | 1.7 | 1.8 | 1.08 | 773698 | 1.4117085 | CS |
4 | -1.16 | -49.7854077253 | 2.33 | 2.99 | 1.08 | 3792857 | 2.18645345 | CS |
12 | 0.48 | 69.5652173913 | 0.69 | 3.961 | 0.2806 | 9980363 | 2.22348207 | CS |
26 | -1.19 | -50.4237288136 | 2.36 | 4.0899 | 0.2806 | 4717889 | 2.20730965 | CS |
52 | -9.366 | -88.8952164009 | 10.536 | 14.4 | 0.2806 | 2531148 | 2.54202532 | CS |
156 | -68.43 | -98.3189655172 | 69.6 | 144.8 | 0.2806 | 1569345 | 47.56766736 | CS |
260 | -12.83 | -91.6428571429 | 14 | 308.8 | 0.2806 | 1732399 | 86.92212263 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales